NCT04679597 2024-10-17
Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure
Institute of Oncology Ljubljana
Completed
Clinical Trials
22 trialsNCT06504875 2024-07-17
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting
NCT06194981 2024-01-12
Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage
The First Affiliated Hospital of Zhengzhou University
Unknown
NCT06169202 2023-12-13
A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
China Medical University, China
Unknown
NCT03451370 2023-11-29
COBRA
Istituto Oncologico Veneto IRCCS
Unknown
NCT05338866 2023-11-22
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator
Sun Yat-sen University
Enrolling by invitation
NCT05176964 2023-09-25
Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer
Fujian Medical University Union Hospital
Unknown
NCT04856761 2022-08-18
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Fudan University
Unknown
NCT05368051 2022-05-10
Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer
Beijing Friendship Hospital
Unknown
NCT02860234 2021-07-23
Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment
Peking University Cancer Hospital & Institute
Completed
NCT04405206 2020-10-14
BJCC-R01
Peking University Cancer Hospital & Institute
Unknown
NCT03923036 2019-04-22
AVOCETTE
University Hospital, Caen
Unknown
NCT01310985 2019-03-01
A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
King Faisal Specialist Hospital & Research Center
Completed
NCT02002195 2019-02-27
MATURE
International Group of Endovascular Oncology
Unknown
NCT03532711 2018-05-22
Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer
Fudan University
Completed
NCT01506167 2018-05-14
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Hoffmann-La Roche
Completed
NCT02479217 2017-02-17
Safety of Xeloda in Solid Tumours
Hoffmann-La Roche
Completed
NCT03015168 2017-01-09
Prognostic Value of Neutrophil-to-lymphocyte Ratio (NLR) on Rectal Cancer Patients
General Hospital of Ningxia Medical University
Completed
NCT01399190 2016-09-28
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Hoffmann-La Roche
Completed
NCT01442155 2016-07-07
An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
Hoffmann-La Roche
Completed
NCT01664494 2016-05-02
An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer
Hoffmann-La Roche
Completed
NCT01311050 2011-12-13
A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
King Faisal Specialist Hospital & Research Center
Unknown